894-895 / 2605
894-895 / 2605
PROG 9509: Phase III trial
•
long-term advantage
in terms of reducing the rate of biochemical failure for patients with low
and intermediate risk prostate cancer
•
no increase in > Grade 3 GI/GU morbidity
over conventional dose conformal treatment
